Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0486 in B-Cell Non-Hodgkin Lymphoma
NCT04594642Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of surovatamig in B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL) and 1 more, sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicities at 28 days, Adverse Events and Serious Adverse Events and 3 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
surovatamig
03
Conditions
B-cell non-Hodgkin lymphomadiffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04594642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594642.